Trial Profile
Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 28 May 2019 Planned End Date changed from 1 Jul 2021 to 30 Apr 2021.
- 28 May 2019 Planned primary completion date changed from 1 Jul 2020 to 30 Apr 2020.
- 28 May 2019 Planned initiation date changed from 1 Jul 2018 to 31 Jul 2019.